GlaxoSmithKline says that Otelixizumab, a Type 1 drug currently under development, has failed in a phase III clinical trial. The drug has been in development in partnership with Tolerx, according to a recent article from Reuters.
The drug was designed for people with newly diagnosed diabetes. However, the drug failed to preserve beta cell function. Analysts had modest expectations for the drug after a similar offering from Eli Lilly failed in October. The company said it would continue to explore different dosing regiments. However, a second similar clinical study has been halted.
As reported by Diabetes Newshound
